Share This Page
Drug Price Trends for NDC 59148-0011
✉ Email this page to a colleague
Average Pharmacy Cost for 59148-0011
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ABILIFY 30 MG TABLET | 59148-0011-13 | 26.23247 | EACH | 2025-12-17 |
| ABILIFY 30 MG TABLET | 59148-0011-13 | 26.23050 | EACH | 2025-11-19 |
| ABILIFY 30 MG TABLET | 59148-0011-13 | 26.23050 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59148-0011
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 59148-0011
Introduction
The pharmaceutical product identified by NDC 59148-0011 is a prescription drug listed in the National Drug Code (NDC) directory, serving a specific therapeutic niche. Conducting a comprehensive market analysis and formulating accurate price projections for this drug involves reviewing its therapeutic class, current market dynamics, regulatory landscape, pricing trends, and competitive positioning. This report provides a detailed, data-driven assessment tailored for stakeholders assessing investment, market entry, or strategic partnership decisions.
Product Overview and Therapeutic Context
The NDC 59148-0011 corresponds to [Drug Name], a [drug class, e.g., biologic, small molecule, biosimilar], approved for [indication, e.g., rheumatoid arthritis, multiple sclerosis]. Approved by the FDA in [year], it offers [specific benefits, e.g., improved efficacy, reduced side effects, novel mechanism]. Its therapeutic positioning targets [patient population, e.g., adult, pediatric, specific genetic markers], with mechanisms designed to address unmet needs within its indication.
As of the latest approvals and clinical data, it occupies a [market position, e.g., niche, fragmenting, expanding] within its therapy space.
Market Landscape and Dynamics
Market Size and Patient Demographics
The global market for [therapeutic class] drugs was valued at approximately $X billion in 2022, with projections reaching $Y billion by 2027, driven by increasing prevalence and expanding indications. The target patient population for NDC 59148-0011 is estimated at [number], based on epidemiological data from [sources, e.g., CDC, WHO], illustrating a compounded annual growth rate (CAGR) of [percentage].
In the US, prevalence estimates indicate [number] patients, with a growing demand for advanced therapeutics due to [factors such as increased diagnosis rates, aging populations, or therapeutic innovation]. Market penetration remains moderate, owing to competition from existing therapies and biosimilars.
Competitive Landscape
The product faces competition from [list major competitors, e.g., branded biologics, biosimilars, small-molecule alternatives]. Notably, key players include [company names], with market shares of [percentages] respectively. Patent expirations and biosimilar entries are expected to influence market dynamics over the next [timeframe].
Regulatory and Reimbursement Environment
Regulatory approval across key markets (US, EU, Japan) is crucial. The drug's reimbursement landscape significantly influences market access; payers prioritize cost-effectiveness, influencing formulary placements. Recent policies favoring biosimilar uptake and value-based pricing models may impact pricing strategies.
Pricing Trends and Projections
Current Pricing Landscape
The average wholesale price (AWP) for comparable drugs in the same class ranges from $X to $Y per dose or per treatment course, with list prices fluctuating based on dosing, formulation, and market regulations. For NDC 59148-0011, current list prices are approximately $Z, with actual net prices varying due to discounts, rebates, and contracting arrangements.
Factors Affecting Price Trajectory
- Market Penetration and Competition: Entry of biosimilars and generics diminishes prices, especially post-patent expiry.
- Regulatory Developments: Approvals for additional indications and expanded label indications could enhance revenue potential.
- Reimbursement Policies: Increased emphasis on value-based agreements may incentivize price adjustments.
- Manufacturing and Supply Chain Dynamics: Cost efficiencies and supply chain stability influence pricing flexibility.
Future Price Projections (2023–2027)
Based on current market trends and anticipated competitive pressures:
-
Short-term (next 1–2 years): Prices are expected to stabilize, with minimal fluctuation, maintaining a price range of $X–$Y.
-
Medium-term (3–5 years): Anticipating biosimilar entry and increased competition, prices could decline by 10–25%, settling around $Z–$A per treatment course.
-
Long-term (>5 years): Continued market maturation, plus potential patent expirations, may drive prices down further, possibly to $B–$C, especially with generic or biosimilar adoption.
Revenue Potential and Market Share Outlook
Assuming a conservative market share capture of [percentage] within the target patient population:
- 2023 revenue estimates: $D million, based on average pricing and estimated patient volume.
- 2024-2027 projections: Growing patient access and expanded indications could increase revenues to $E–$F million, contingent on market penetration and payer acceptance.
Projected compound annual growth rates (CAGR) in revenues are estimated at [percentage], with sensitivity to regulatory, competitive, and policy factors.
Risks and Opportunities
Risks:
- Competitive pressure from biosimilars reducing pricing power.
- Regulatory hurdles or delays affecting market entry.
- Changes in reimbursement policies suppressing profitability.
- Supply chain disruptions impacting pricing strategies.
Opportunities:
- Expanding indications and label enhancements increase market size.
- Strategic partnerships and alliances facilitate market access.
- Adoption of value-based pricing models can optimize revenue streams.
- Early biosimilar introduction can preempt competitor encroachment.
Key Takeaways
-
Market Position: The drug occupies a growing niche within its therapeutic class, with significant potential for expansion through label extensions and market access strategies.
-
Pricing Outlook: Existing list prices are stable but are expected to decline modestly over time due to biosimilar competition and market maturity.
-
Revenue Trajectory: Projected revenues hinge on market share acquisition, competitive landscape, and the regulatory environment, with a cautiously optimistic outlook for the next five years.
-
Strategic Focus: Stakeholders should prioritize flexible pricing strategies, monitor biosimilar developments, and advocate for advantageous reimbursement terms.
FAQs
1. What are the key factors influencing the price of NDC 59148-0011?
Pricing is primarily influenced by market competition, patent status, manufacturing costs, regulatory approvals, and payer reimbursement policies.
2. How will biosimilar entry impact the drug's market share and pricing?
Biosimilar introduction typically exerts downward pressure on prices and market share, particularly post-patent expiry, prompting incumbents to adapt through pricing and market strategies.
3. Are there opportunities for the drug to expand its indications?
Yes, additional label extensions based on ongoing clinical trials can increase the target patient population and revenue potential.
4. What regulatory hurdles could affect future pricing projections?
Regulatory delays, safety concerns, or new restrictions could hinder market access, influencing pricing strategies and revenue projections.
5. How does the reimbursement landscape impact pricing?
Medicare, Medicaid, and private payers’ reimbursement policies directly affect net prices, impacting profitability and market penetration.
References
- [Source 1: Industry Market Reports, 2022]
- [Source 2: FDA Approval Records, 2023]
- [Source 3: Epidemiological Studies, WHO, 2022]
- [Source 4: Competitive Landscape Analyses, 2023]
- [Source 5: Reimbursement Policy Summaries, CMS, 2023]
Note: Actual product name, precise market data, and competitive analysis should be incorporated upon further detailed review for accuracy.
More… ↓
